Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2023 Filed Mar 15, 2023 21:00 UTC |
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionOption (Right to Buy) · Derivative | 21,810 | $54.86 Strike: $54.86 | $1,196,496.60 |
DisclosureSEC source: 0001415889-23-004956 · form4-03152023_050301.xml · derivative · entry 5 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,810 shares Expires 2026-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section16 under Rule 16b-3. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:00 UTC |
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER
|
SaleCommon Stock, $0.01 par value | 31,315 | $152.27 | $4,768,335.05 |
DisclosureSEC source: 0001415889-23-004956 · form4-03152023_050301.xml · nonDerivative · entry 3 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,941 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:00 UTC |
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER
|
SaleCommon Stock, $0.01 par value | 21,810 | $152.30 | $3,321,663.00 |
DisclosureSEC source: 0001415889-23-004956 · form4-03152023_050301.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,256 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 13, 2023 Filed Mar 15, 2023 21:00 UTC |
Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock, $0.01 par value | 21,810 | $54.86 | $1,196,496.60 |
DisclosureSEC source: 0001415889-23-004956 · form4-03152023_050301.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2023 Filed Mar 7, 2023 22:00 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
Tax withholdingCommon Stock, $0.01 par value | 449 | $156.06 | $70,070.94 |
DisclosureSEC source: 0001415889-23-004428 · form4-03072023_050303.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,900 Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 17:00 UTC |
GONZALEZ RICHARD ADirector · CHAIRMAN OF THE BOARD AND CEO
|
GiftCommon Stock, $0.01 par value | 2,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004429 · form4-03072023_050306.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,794 Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 22:08 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
Tax withholdingCommon Stock, $0.01 par value | 810 | $155.27 | $125,768.70 |
DisclosureSEC source: 0001415889-23-003857 · form4-03022023_100349.xml · nonDerivative · entry 2 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,349 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC |
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICER
|
SaleCommon stock, $0.01 par value | 16,746 | $153.62 | $2,572,520.52 |
DisclosureSEC source: 0001415889-23-003820 · form4-03022023_040302.xml · nonDerivative · entry 3 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,837 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.37 to $154.13, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:30 UTC |
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICER
|
SaleCommon stock, $0.01 par value | 27,395 | $153.08 | $4,193,582.77 |
DisclosureSEC source: 0001415889-23-003820 · form4-03022023_040302.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,583 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:01 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
Exercise / conversionOption (Right to Buy) · Derivative | 26,990 | $51.42 Strike: $51.42 | $1,387,825.80 |
DisclosureSEC source: 0001415889-23-003851 · form4-03022023_100335.xml · derivative · entry 8 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,990 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:01 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
SaleCommon Stock, $0.01 par value | 780 | $153.39 | $119,644.20 |
DisclosureSEC source: 0001415889-23-003851 · form4-03022023_100335.xml · nonDerivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,849 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.37 to $153.47, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:01 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
SaleCommon Stock, $0.01 par value | 9,220 | $153.05 | $1,411,121.00 |
DisclosureSEC source: 0001415889-23-003851 · form4-03022023_100335.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,629 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:01 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
SaleCommon Stock, $0.01 par value | 26,990 | $155.00 | $4,183,450.00 |
DisclosureSEC source: 0001415889-23-003851 · form4-03022023_100335.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,849 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:01 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
Exercise / conversionCommon Stock, $0.01 par value | 26,990 | $51.42 | $1,387,825.80 |
DisclosureSEC source: 0001415889-23-003851 · form4-03022023_100335.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:04 UTC |
Reents Scott TEVP, CHIEF FINANCIAL OFFICER
|
SaleCommon Stock, $0.01 par value | 850 | $153.38 | $130,373.00 |
DisclosureSEC source: 0001415889-23-003854 · form4-03022023_100328.xml · nonDerivative · entry 3 Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.37 to $153.47, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:04 UTC |
Reents Scott TEVP, CHIEF FINANCIAL OFFICER
|
SaleCommon Stock, $0.01 par value | 15,092 | $153.06 | $2,309,981.52 |
DisclosureSEC source: 0001415889-23-003854 · form4-03022023_100328.xml · nonDerivative · entry 2 Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,659 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:06 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
SaleCommon Stock, $0.01 par value | 805 | $153.38 | $123,470.90 |
DisclosureSEC source: 0001415889-23-003855 · form4-03022023_100358.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,377 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.36 to $153.43, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:06 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
SaleCommon Stock, $0.01 par value | 11,330 | $153.06 | $1,734,169.80 |
DisclosureSEC source: 0001415889-23-003855 · form4-03022023_100358.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,182 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:07 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
Exercise / conversionOption (Right to Buy) · Derivative | 15,003 | $93.50 Strike: $93.50 | $1,402,780.50 |
DisclosureSEC source: 0001415889-23-003856 · form4-03022023_100350.xml · derivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,003 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:07 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
SaleCommon Stock, $0.01 par value | 15,003 | $155.00 | $2,325,465.00 |
DisclosureSEC source: 0001415889-23-003856 · form4-03022023_100350.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,829 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:07 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
Exercise / conversionCommon Stock, $0.01 par value | 15,003 | $93.50 | $1,402,780.50 |
DisclosureSEC source: 0001415889-23-003856 · form4-03022023_100350.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:30 UTC |
RICHMOND TIMOTHY J.EVP, CHIEF HR OFFICER
|
Tax withholdingCommon stock, $0.01 par value | 35,111 | $154.28 | $5,416,925.08 |
DisclosureSEC source: 0001415889-23-003820 · form4-03022023_040302.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,978 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:30 UTC |
Michael Robert A.VICE CHAIRMAN
|
Tax withholdingCommon Stock, $0.01 par value | 48,335 | $154.28 | $7,457,123.80 |
DisclosureSEC source: 0001415889-23-003821 · form4-03022023_040309.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VICE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,645 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:30 UTC |
GONZALEZ RICHARD ADirector · CHAIRMAN OF THE BOARD AND CEO
|
Tax withholdingCommon Stock, $0.01 par value | 113,810 | $154.28 | $17,558,606.80 |
DisclosureSEC source: 0001415889-23-003822 · form4-03022023_040314.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,344 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:35 UTC |
Hudson Thomas JSVP, R&D AND CSO
|
Tax withholdingCommon Stock, $0.01 par value | 27,922 | $154.28 | $4,307,806.16 |
DisclosureSEC source: 0001415889-23-003844 · form4-03022023_040301.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,329 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:01 UTC |
SALEKI-GERHARDT AZITAEVP, OPERATIONS
|
Tax withholdingCommon Stock, $0.01 par value | 33,359 | $154.28 | $5,146,626.52 |
DisclosureSEC source: 0001415889-23-003851 · form4-03022023_100335.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · EVP, OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,849 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:02 UTC |
Stewart Jeffrey RyanEVP, COMMERCIAL OPERATIONS
|
Tax withholdingCommon Stock, $0.01 par value | 24,910 | $154.28 | $3,843,114.80 |
DisclosureSEC source: 0001415889-23-003852 · form4-03022023_100330.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,256 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:03 UTC |
Durkin Brian LVP, CONTROLLER
|
Tax withholdingCommon Stock, $0.01 par value | 11,182 | $154.28 | $1,725,158.96 |
DisclosureSEC source: 0001415889-23-003853 · form4-03022023_100331.xml · nonDerivative · entry 1 Durkin Brian L · CIK 0001756865 · VP, CONTROLLER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,149 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:04 UTC |
Reents Scott TEVP, CHIEF FINANCIAL OFFICER
|
Tax withholdingCommon Stock, $0.01 par value | 12,683 | $154.28 | $1,956,733.24 |
DisclosureSEC source: 0001415889-23-003854 · form4-03022023_100328.xml · nonDerivative · entry 1 Reents Scott T · CIK 0001937048 · EVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,751 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:06 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
Tax withholdingCommon Stock, $0.01 par value | 9,656 | $154.28 | $1,489,727.68 |
DisclosureSEC source: 0001415889-23-003855 · form4-03022023_100358.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,512 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:07 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
Tax withholdingCommon Stock, $0.01 par value | 19,850 | $154.28 | $3,062,458.00 |
DisclosureSEC source: 0001415889-23-003856 · form4-03022023_100350.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,829 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:08 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
Tax withholdingCommon Stock, $0.01 par value | 5,762 | $154.28 | $888,961.36 |
DisclosureSEC source: 0001415889-23-003857 · form4-03022023_100349.xml · nonDerivative · entry 1 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,159 Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:12 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
Exercise / conversionOption (Right to Buy) · Derivative | 15,321 | $105.92 Strike: $105.92 | $1,622,800.32 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · derivative · entry 9 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,660 Underlying: Common Stock · 15,321 shares Expires 2031-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:12 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
SaleCommon Stock, $0.01 par value | 8,420 | $151.29 | $1,273,861.80 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 7 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,679 F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.53, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:12 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
SaleCommon Stock, $0.01 par value | 6,901 | $150.74 | $1,040,256.74 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 6 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,099 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:12 UTC |
Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS
|
Exercise / conversionCommon Stock, $0.01 par value | 15,321 | $105.92 | $1,622,800.32 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 5 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
Exercise / conversionOption (Right to Buy) · Derivative | 6,370 | $67.25 Strike: $67.25 | $428,382.50 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · derivative · entry 13 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,370 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
Exercise / conversionOption (Right to Buy) · Derivative | 7,809 | $56.93 Strike: $56.93 | $444,566.37 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · derivative · entry 12 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,809 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
SaleCommon Stock, $0.01 par value | 400 | $151.34 | $60,536.00 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 10 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,921 F8 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.15 to $151.42, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
SaleCommon Stock, $0.01 par value | 567 | $150.78 | $85,492.26 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 9 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,321 F7 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.10, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
SaleCommon Stock, $0.01 par value | 7,646 | $151.29 | $1,156,763.34 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 8 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,888 F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
SaleCommon Stock, $0.01 par value | 6,533 | $150.74 | $984,784.42 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 7 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,534 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
SaleCommon Stock, $0.01 par value | 7,780 | $151.28 | $1,176,958.40 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 6 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,067 F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
SaleCommon Stock, $0.01 par value | 5,615 | $150.71 | $846,236.65 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 5 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,847 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
Exercise / conversionCommon Stock, $0.01 par value | 6,370 | $67.25 | $428,382.50 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 4 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:14 UTC |
Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH
|
Exercise / conversionCommon Stock, $0.01 par value | 7,809 | $56.93 | $444,566.37 |
DisclosureSEC source: 0001415889-23-002946 · form4-02212023_110208.xml · nonDerivative · entry 3 Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:00 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
Exercise / conversionOption (Right to buy) · Derivative | 7,364 | $93.50 Strike: $93.50 | $688,534.00 |
DisclosureSEC source: 0001415889-23-003007 · form4-02222023_050201.xml · derivative · entry 4 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,364 shares Expires 2033-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:00 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
SaleCommon Stock, $0.01 par value | 3,933 | $151.29 | $595,023.57 |
DisclosureSEC source: 0001415889-23-003007 · form4-02222023_050201.xml · nonDerivative · entry 3 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,168 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.49, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:00 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
SaleCommon Stock, $0.01 par value | 3,431 | $150.73 | $517,154.63 |
DisclosureSEC source: 0001415889-23-003007 · form4-02222023_050201.xml · nonDerivative · entry 2 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,101 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 22:00 UTC |
Siatis Perry CEVP, GC AND SECRETARY
|
Exercise / conversionCommon Stock, $0.01 par value | 7,364 | $93.50 | $688,534.00 |
DisclosureSEC source: 0001415889-23-003007 · form4-02222023_050201.xml · nonDerivative · entry 1 Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.